In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5–MYC Axis

Günter Schneider; Dieter Saur

doi:10.1016/j.trecan.2016.07.002

In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5–MYC Axis

Günter Schneider
, Dieter Saur

Medicine and Health

Technical University of Munich
German Cancer Research Center

Research output: Contribution to journal › Short survey › peer-review

2 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200 000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to develop a novel genetic mouse system, termed Patient-Based In Vivo Lethality to Optimize Treatment (PILOT), to perform functional RNAi-based in vivo screens to uncover and target PDAC drivers. In a forward genetic screen focused on epigenetic modifiers, a WDR5–Myc axis that regulates the DNA replication checkpoint was identified and exploited in vivo for therapeutic intervention.

Original language	English
Pages (from-to)	391-392
Number of pages	2
Journal	Trends in Cancer
Volume	2
Issue number	8
DOIs	https://doi.org/10.1016/j.trecan.2016.07.002
State	Published - 1 Aug 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.trecan.2016.07.002

Cite this

@article{f63ea5af95724e7d9ea3d6a425e59a15,

title = "In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5–MYC Axis",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200 000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to develop a novel genetic mouse system, termed Patient-Based In Vivo Lethality to Optimize Treatment (PILOT), to perform functional RNAi-based in vivo screens to uncover and target PDAC drivers. In a forward genetic screen focused on epigenetic modifiers, a WDR5–Myc axis that regulates the DNA replication checkpoint was identified and exploited in vivo for therapeutic intervention.",

author = "G{\"u}nter Schneider and Dieter Saur",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.trecan.2016.07.002",

language = "English",

volume = "2",

pages = "391--392",

journal = "Trends in Cancer",

issn = "2405-8033",

publisher = "Cell Press",

number = "8",

}

TY - JOUR

T1 - In Vivo RNAi Screening for Pancreatic Cancer Drivers

T2 - PILOTing the WDR5–MYC Axis

AU - Schneider, Günter

AU - Saur, Dieter

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200 000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to develop a novel genetic mouse system, termed Patient-Based In Vivo Lethality to Optimize Treatment (PILOT), to perform functional RNAi-based in vivo screens to uncover and target PDAC drivers. In a forward genetic screen focused on epigenetic modifiers, a WDR5–Myc axis that regulates the DNA replication checkpoint was identified and exploited in vivo for therapeutic intervention.

AB - Pancreatic ductal adenocarcinoma (PDAC) represents a major global health problem that causes over 200 000 deaths each year worldwide. The disease is highly resistant to cytotoxic and targeted therapies and the average survival is less than 12 months. This situation prompted Alessandro Carugo and Giulio Draetta to develop a novel genetic mouse system, termed Patient-Based In Vivo Lethality to Optimize Treatment (PILOT), to perform functional RNAi-based in vivo screens to uncover and target PDAC drivers. In a forward genetic screen focused on epigenetic modifiers, a WDR5–Myc axis that regulates the DNA replication checkpoint was identified and exploited in vivo for therapeutic intervention.

UR - https://www.scopus.com/pages/publications/84978864701

U2 - 10.1016/j.trecan.2016.07.002

DO - 10.1016/j.trecan.2016.07.002

M3 - Short survey

C2 - 28741490

AN - SCOPUS:84978864701

SN - 2405-8033

VL - 2

SP - 391

EP - 392

JO - Trends in Cancer

JF - Trends in Cancer

IS - 8

ER -

In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5–MYC Axis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this